For media queries only regarding Cytisine, please email consilient-health@foxandcat.online. For any other queries, please email infouk@consilienthealth.com
All the latest news and events
Newsletter signup
Keep up to date with news about Consilient Health and the healthcare sector.
SignupNews
Consilient Health are pleased to announce that Karen Pulley is now Head of Sustainability. Karen explains that Sustainability is something […]
On 10th November 2022, Consilient Health Ltd entered a distribution and promotional partnership with Italfarmaco Group for Blissel®, its vaginal […]
The company’s ‘Menopause in the Workplace’ policy is just one of the reasons why employees at Consilient Health believe they […]
On 8th March, we celebrate International Women’s Day; a day that marks the achievements of women across the world and […]
We’re delighted to announce that Consilient Health has been awarded a place on the UK’s Best Workplaces™ for Wellbeing list […]
Consilient Health has made a donation to a Richmond-based charity that helps to fund the education of medical students nationwide. […]
Consilient Health is pleased to announce it has taken over the UK marketing of Detrunorm® (Propiverine)
As of January 2022, Consilient Health is pleased to announce it has taken over the UK marketing of Detrunorm® (Propiverine) in conjunction with our partner Apogepha.
Available in the 15mg x 56 tablets, 30mg x 28 MR Capsules, and 45mg x 28 MR Capsules,
All 3 SKU’s are available through Alliance wholesale.
For product details please visit our products page
